{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05066672",
            "orgStudyIdInfo": {
                "id": "NAV-17A-007"
            },
            "secondaryIdInfos": [
                {
                    "id": "SPN820",
                    "type": "OTHER",
                    "domain": "Supernus Pharmaceuticals, Inc."
                }
            ],
            "organization": {
                "fullName": "Navitor Pharmaceuticals, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression",
            "officialTitle": "A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NV-5138 in Adults With Treatment Resistant Depression",
            "therapeuticArea": [
                "Mental Health"
            ],
            "study": "phase-study-of-nv-in-adults-with-treatment-resistant-depression"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-11",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-02-28",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-09-23",
            "studyFirstSubmitQcDate": "2021-09-23",
            "studyFirstPostDateStruct": {
                "date": "2021-10-04",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-11-08",
            "lastUpdatePostDateStruct": {
                "date": "2023-11-09",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Navitor Pharmaceuticals, Inc.",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Supernus Pharmaceuticals, Inc.",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study will evaluate the efficacy and safety of NV-5138 in adults with TRD",
            "detailedDescription": "The is a multicenter, randomized, double-blind, flexible- dose, placebo-controlled, parallel design of adjunctive NV-5138 in adults with TRD."
        },
        "conditionsModule": {
            "conditions": [
                "Treatment Resistant Depression"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "randomized, double-blind, placebo-controlled",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "maskingDescription": "matched placebo",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 400,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "NV-5138 400 mg oral capsules",
                    "type": "EXPERIMENTAL",
                    "description": "Either 2 or 4 400 mg oral capsules administered once daily",
                    "interventionNames": [
                        "Drug: NV-5138"
                    ]
                },
                {
                    "label": "matched placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "2 or 4 oral capsules administered once daily",
                    "interventionNames": [
                        "Drug: matched placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "NV-5138",
                    "description": "NV-5138 is a novel, orally bioavailable, selective, direct activator of mTORC1 cellular signaling",
                    "armGroupLabels": [
                        "NV-5138 400 mg oral capsules"
                    ],
                    "otherNames": [
                        "SPN820"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "matched placebo",
                    "description": "matched placebo oral capsules",
                    "armGroupLabels": [
                        "matched placebo"
                    ],
                    "otherNames": [
                        "placebo",
                        "PBO"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Evaluation of the efficacy of NV-5138 as measured by the Montgomery-Asberg Depression Rating scale",
                    "description": "Change from Baseline to end of treatment period on the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score. MADRS captures a clinician-rated score on a seven-point Likert scale for a score ranging from 0 to 60, with higher scores reflecting greater depression severity.",
                    "timeFrame": "5 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Evaluation of the efficacy as measured by Clinical Global Impression-Severity (CGI-s) score",
                    "description": "Change from baseline to end of treatment period on the Clinical Global Impression-Severity score for NV-5138 treated patients as compared to placebo. The CGI-S is a clinican-rated seven point scale from 0-7 where a higher rating represents higher severity of illness.",
                    "timeFrame": "5 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female, aged 18 to 70 years at Screening.\n* Diagnosis of Major Depressive Disorder (MDD) according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) for either recurrent or single episode MDD without psychotic features that is confirmed by the Mini International Neuropsychiatric Interview (MINI).\n* Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of \u226526 for the current MDE at all Screening visits and Baseline (Day 1).\n* CGI-S score of \u22654 (moderately ill or worse) at all Screening visits and Baseline.\n* History of inadequate response to \u22652 but \u22644 prior ADT therapies (including the current ADT for the current MDE) \u2265 2 weeks at Screening and \u2265 8 weeks at Baseline.\n* Stable therapeutic dose of one of the following ADTs for the current MDE for \u22652 weeks prior to Screening and maintain the therapeutic dose throughout the study: citalopram, escitalopram, paroxetine, fluoxetine, sertraline, duloxetine, venlafaxine (IR or XR), desvenlafaxine, or vortioxetine.\n* Detectable blood level of the approved ADT at Visits 1 and 2 of the Screening Period.\n\nExclusion Criteria:\n\n* MADRS Total Score improvement of \u226525% from the highest to the lowest score at any visit during the Screening Period.\n* Clinically significant abnormal laboratory profiles, vital signs, or electrocardiograms (ECGs), per Investigator judgment.\n* Judged by the Investigator to be at significant risk for suicide, violence, or homicide; or answers 'Yes' to items 4 or 5 on the Suicidal Ideation section of the C-SSRS at Screening or at Baseline; or has attempted suicide within the 6 months prior to Screening.\n* History of psychotic disorder, including but not limited to schizophrenia, MDD with psychotic features, or bipolar I/II disorder with psychotic features.\n* History of PTSD, OCD, panic disorder, intellectual disability, autism, acute stress disorder, or Cluster A or B personality disorder (per DSM-5 criteria).\n* Any condition or procedure that may interfere with the absorption, metabolism, or elimination of the study medication (e.g., cholecystectomy or gastric bypass).\n* In the Investigator's opinion, is unlikely to comply with the protocol or is unsuitable for any other reason.\n* History of alcohol and/or substance use disorder within 6 months prior to Screening or is currently using or has positive results at Screening for drugs of abuse or has a positive alcohol result at any Screening or Baseline visit.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "70 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Samuel Schaffer, MD",
                    "role": "CONTACT",
                    "phone": "240-403-5758",
                    "email": "samuel.schaffer@premier-research.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Randy Owen, MD",
                    "affiliation": "Medical Monitor",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Northwest Clinical Research Center, Inc.",
                    "status": "RECRUITING",
                    "city": "Bellevue",
                    "state": "Washington",
                    "zip": "98007",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Rachel Hall",
                            "role": "CONTACT",
                            "email": "rhall@nwcrc.net"
                        },
                        {
                            "name": "Arifulla Khan",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 47.61038,
                        "lon": -122.20068
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003863",
                    "term": "Depression"
                },
                {
                    "id": "D000003866",
                    "term": "Depressive Disorder"
                },
                {
                    "id": "D000061218",
                    "term": "Depressive Disorder, Treatment-Resistant"
                }
            ],
            "ancestors": [
                {
                    "id": "D000001526",
                    "term": "Behavioral Symptoms"
                },
                {
                    "id": "D000019964",
                    "term": "Mood Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7058",
                    "name": "Depression",
                    "asFound": "Depression",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7061",
                    "name": "Depressive Disorder",
                    "asFound": "Depression",
                    "relevance": "HIGH"
                },
                {
                    "id": "M29783",
                    "name": "Depressive Disorder, Treatment-Resistant",
                    "asFound": "Treatment Resistant Depression",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4818",
                    "name": "Behavioral Symptoms",
                    "relevance": "LOW"
                },
                {
                    "id": "M21835",
                    "name": "Mood Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}